Current Suspected Overdose Deaths in Delaware for 2021: Get Help Now!
Division of Public Health COVID-19 Testing Data Breach Call Center: 1-833-791-1663 (9 a.m.-9 p.m. Mon-Fri)
In 2005, the Division of Medicaid & Medical Assistance (DMMA) implemented a preferred drug list (PDL). The PDL is composed of drugs that are medically appropriate and less expensive than other drugs in the same class. The drugs are chosen for inclusion on the list by a Pharmaceutical and Therapeutics Committee (P&T Committee). The P&T membership includes clinicians from various specialty areas and includes public advocates. The committee’s objective is to achieve quality pharmaceutical care for recipients enrolled in Delaware’s Medical Assistance programs while providing significant taxpayer savings. The P&T Committee meets periodically to review monographs and literature and make recommendations to the Division regarding drugs to be considered for inclusion on (or deletion from) the PDL.
P&T Committee meetings are open to the public. Prior registration is required for anyone wishing to give public testimony. For information on registration, consult the Delaware Medicaid Public Testimony Guidelines.
The P&T Committee’s official agenda (including the time and place of the next meeting) and minutes can be found at the Delaware Medicaid Pharmacy webpage, which also provides access to the committee’s complete bylaws and a list of committee members. If you are not able to access any of the documents above, please contact DMMA for a printed copy.
Please note: Some of the files available on this page are in Adobe PDF format which requires Adobe Acrobat Reader. A free copy of Adobe Acrobat Reader can be downloaded directly from Adobe . If you are using an assistive technology unable to read Adobe PDF, please either view the corresponding text only version (if available) or visit Adobe's Accessibility Tools page.